$70 Million Will Fund Tobacco Study Centers at Seven Universities

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 12
Volume 8
Issue 12

BETHESDA, Md-Two components of the National Institutes of Health will spend about $70 million over 5 years to fund Transdisciplinary Tobacco Use Research Centers at seven universities. The first year’s grants from the National Cancer Institute and the National Institute on Drug Abuse (NIDA) will total $14.5 million. In addition, the Robert Wood Johnson Foundation has committed another $14 million over the 5 years.

BETHESDA, Md—Two components of the National Institutes of Health will spend about $70 million over 5 years to fund Transdisciplinary Tobacco Use Research Centers at seven universities. The first year’s grants from the National Cancer Institute and the National Institute on Drug Abuse (NIDA) will total $14.5 million. In addition, the Robert Wood Johnson Foundation has committed another $14 million over the 5 years.

The overall goal of the program is to find new ways to combat tobacco use and its consequences. Centers will be established at Brown University, the University of California, Irvine, the University of Southern California, Georgetown University, the University of Minnesota, the University of Wisconsin, and Yale University.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content